ECOSPOR III - SER-109 Versus Placebo in the Treatment of Adults With Recurrent Clostridium Difficile Infection
Public ClinicalTrials.gov record NCT03183128. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3 Multicenter, RandomizeEd, Double Blind, Placebo COntrolled, Parallel Group Study to Evaluate the Safety, Tolerability, & Efficacy of SER-109 vs. Placebo to Reduce Recurrence of ClOstRidium Difficile Infection (CDI) in Adults
Study identification
- NCT ID
- NCT03183128
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Seres Therapeutics, Inc.
- Industry
- Enrollment
- 182 participants
Conditions and interventions
Conditions
Interventions
- SER-109 Biological
- Placebo Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 9, 2017
- Primary completion
- Jul 2, 2020
- Completion
- Sep 28, 2020
- Last update posted
- Apr 26, 2023
2017 – 2020
United States locations
- U.S. sites
- 51
- U.S. states
- 25
- U.S. cities
- 49
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| (Investigator site) | North Little Rock | Arkansas | 72117 | — |
| (Investigator site) | Mather | California | 95655 | — |
| (Investigator site) | Mountain View | California | 94040 | — |
| (Investigator site) | Northridge | California | 91324 | — |
| (Investigator site) | Sacramento | California | 95817 | — |
| (Investigator site) | Simi Valley | California | 93065 | — |
| (Investigator site) | Upland | California | 91786 | — |
| (Investigator site) | Hamden | Connecticut | 06518 | — |
| (Investigator site) | Washington D.C. | District of Columbia | 20007 | — |
| (Investigator site) | Jacksonville | Florida | 32256 | — |
| (Investigator site) | Miami | Florida | 33015 | — |
| (Investigator site) | Miami | Florida | 33155 | — |
| (Investigator site) | Pembroke Pines | Florida | 33024 | — |
| (Investigator site) | Pembroke Pines | Florida | 33026 | — |
| (Investigator site) | Athens | Georgia | 30607 | — |
| (Investigator site) | Atlanta | Georgia | 30322 | — |
| (Investigator site) | Marietta | Georgia | 30060 | — |
| (Investigator site) | Riverdale | Georgia | 30274 | — |
| (Investigator site) | Sandy Springs | Georgia | 30342 | — |
| (Investigator site) | Idaho Falls | Idaho | 83404 | — |
| (Investigator site) | Springfield | Illinois | 62703 | — |
| (Investigator site) | Evansville | Indiana | 47714 | — |
| (Investigator site) | Jeffersonville | Indiana | 47130 | — |
| (Investigator site) | Iowa City | Iowa | 52242 | — |
| (Investigator site) | Kansas City | Kansas | 66160 | — |
| (Investigator site) | New Orleans | Louisiana | 70121 | — |
| (Investigator site) | Annapolis | Maryland | 21401 | — |
| (Investigator site) | Chevy Chase | Maryland | 20814 | — |
| (Investigator site) | Boston | Massachusetts | 02144 | — |
| (Investigator site) | Worcester | Massachusetts | 01655 | — |
| (Investigator site) | Detroit | Michigan | 48202 | — |
| (Investigator site) | Royal Oak | Michigan | 48073 | — |
| (Investigator site) | St Louis | Missouri | 63141 | — |
| (Investigator site) | Butte | Montana | 59701 | — |
| (Investigator site) | Las Vegas | Nevada | 89119 | — |
| (Investigator site) | Buffalo | New York | 14215 | — |
| (Investigator site) | Greenville | North Carolina | 27834 | — |
| (Investigator site) | Kinston | North Carolina | 28501 | — |
| (Investigator site) | Raleigh | North Carolina | 27607 | — |
| (Investigator site) | Centerville | Ohio | 45459 | — |
| (Investigator site) | Cleveland | Ohio | 44195 | — |
| (Investigator site) | Columbus | Ohio | 43215 | — |
| (Investigator site) | Pittsburgh | Pennsylvania | 15213 | — |
| (Investigator site) | Sayre | Pennsylvania | 18840 | — |
| (Investigator site) | Houston | Texas | 77098 | — |
| (Investigator site) | San Antonio | Texas | 78234 | — |
| (Investigator site) | Southlake | Texas | 76092 | — |
| (Investigator site) | Bountiful | Utah | 84010 | — |
| (Investigator site) | Riverton | Utah | 84065 | — |
| (Investigator site) | Charlottesville | Virginia | 22908 | — |
| (Investigator site) | Reston | Virginia | 20191 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 5 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03183128, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 26, 2023 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03183128 live on ClinicalTrials.gov.